Lumida
/CRVS
⌘K
Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

CRVS
$14.90USD+4.41%+0.63 today

MARKET CAP

1.3B

P/E (TTM)

FWD P/E

DAY RANGE

$14 – $15

52W RANGE

$4
$27

AI Summary

Stalk
Buy NowMedium

A Stage 2 advancing context persists with a clear Lockout Rally driving forced participation above rising 9EMA, 20EMA, and 50DMA. Price is extended but the Lockout Rally override supports continued upside without typical exhaustion constraints. Medium- and short-term biases align bullish, presenting favorable conditions for Buy Now. Key risks include a deep pullback breaching EMA support and moderate transition risk toward Stage 3.

  • Phase I atopic dermatitis Cohort 3 yielded a 64.8% EASY score reduction vs. 40% placebo.
  • Raised $189 M via public offering; cash balance $56.8 M funds operations into 2026.
  • Q4 2025 R&D expenses rose to $9.9 M, driving net loss to $12.3 M.
Full analysis →
Insider Trades6 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
May 18, 2026BuyCRVSRichard A Md MillerPresident and CEO6,932$12.04$1.3B-44.71%+276.26%$83.5K+0.29%Buy Now
Jun 4, 2025BuyCRVSWilliam Benton Jones19,357$3.50$1.3B-44.71%+276.26%$67.7K+12.59%Buy Now
May 7, 2025BuyCRVSRichard A Md MillerPresident and CEO559,073$3.50$1.3B-44.71%+276.26%$2.0M+96.79%Buy Now
May 10, 2024SellCRVSRichard A Md MillerPresident and CEO302,016$2.08$1.3B-44.71%+276.26%$628.2K-20.27%Buy Now
May 6, 2024BuyCRVSWilliam Benton Jones20,000$1.73$1.3B-44.71%+276.26%$34.6K+13.06%Buy Now
May 6, 2024BuyCRVSRichard A Md MillerPresident and CEO577,634$1.73$1.3B-44.71%+276.26%$1.0M+103.32%Buy Now